Live corpus
Active intelligence prompt Pediatric cancer: surface high-value therapeutic signals across pediatric oncology literature.
PEDIATRIC CANCER RESEARCH INTELLIGENCE

Finding therapies hidden in 40,255 pediatric cancer papers.

Neurocompute scores pediatric oncology literature, surfaces overlooked therapeutic signals, and turns fragmented childhood cancer research into a living discovery terminal.

40,255 Papers indexed
1,440 Papers AI scored
40,255 Ranked papers
100.0% Coverage
PATIENT-FRIENDLY SUMMARY

CHIP-AML22: a complex clinical trial in de novo pediatric AML patients, including a gemtuzumab ozogamicin randomization and targeted therapy with quizartinib in eligible subgroups, within the NOPHO-DB-SHIP consortium.

For education only—not personal medical advice.

LIVE PEDIATRIC ONCOLOGY INTELLIGENCE
↑ Therapeutic signals emerging ↑ New pediatric cancer papers ingested ↑ Cross-paper convergence detected ↑ Human relevance scores updating ↑ Overlooked treatment paths surfacing
TOP PEDIATRIC CANCER SIGNALS

Ranked Discovery Journal Articles

View all discoveries →
LATEST PEDIATRIC CANCER PAPERS

Database feed

Last ingest 2026-11-09 10:15 AM
PEDIATRIC CANCER RESEARCH TERMINAL

All ranked pediatric cancer papers

40255 results
D
AI -
Standard 52.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 30.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
A novel IKZF1::FAM3C fusion associated with inversion of chromosome 7, inv(7)(p13q32), in relapsed acute myeloid leukemia.
PMID 41269428 Published: 2025-11-21 Ingested: 2026-08-02 12:05 AM Journal of hematopathology
AI -
Standard 52.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 35.1; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
A Rare Case of Refractory Nodal Marginal Zone Lymphoma in a Child, Successfully Cured by Allogeneic Stem Cell Transplant: A Case Report.
PMID 39168814 Published: 2024-09-01 Ingested: 2026-08-02 12:02 AM Pediatric transplantation
AI -
Standard 52.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 30.0; human relevance: 80.0; therapeutic relevance: 40.1; sample size: 20.0; recency: 90.0; abstract quality: 85.0.

D
Rare case of chronic lymphocytic leukemia in an adolescent treated with targeted therapy.
PMID 38872414 Published: 2024-06-14 Ingested: 2026-08-02 12:02 AM Pediatric blood & cancer
AI -
Standard 52.52
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 45.1; sample size: 20.0; recency: 80.0; abstract quality: 0.0.

D
Targeting of the oncogenic fusion EWSR1-FLI1 in Ewing Sarcoma by CRISPR/dCas9 silencers.
PMID 42675859 Published: 2026-08-31 Ingested: 2026-09-03 09:15 AM Molecular therapy : the journal of the American Society of Gene Therapy
AI -
Standard 52.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 30.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Gynaecomastia in a patient with Peutz-Jeghers syndrome.
PMID 42493218 Published: 2026-07-23 Ingested: 2026-08-02 12:07 AM BMJ case reports
AI -
Standard 52.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 55.0; human relevance: 85.0; therapeutic relevance: 15.0; sample size: 20.0; recency: 100.0; abstract quality: 40.0.

D
Machine learning and metabolic modeling-based identification of hypoxia-driven metabolic signatures in pediatric cancers.
PMID 42147321 Published: 2026-04-30 Ingested: 2026-08-02 12:06 AM Frontiers in pharmacology
AI -
Standard 52.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 30.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

D
Two decades of mucormycosis: molecular epidemiology and antifungal susceptibility trends in Türkiye.
PMID 41868144 Published: 2026-03-06 Ingested: 2026-08-02 12:06 AM Frontiers in cellular and infection microbiology
AI -
Standard 52.5
Final -
AI Summary

This pediatric cancer paper has not been AI summarized yet.

Why It Matters

Deterministic evidence score: 52.5/100. Study design: 50.0; human relevance: 55.0; therapeutic relevance: 30.0; sample size: 20.0; recency: 100.0; abstract quality: 85.0.

Previous
Page 2809 of 3355
Next
Before you continue

AI-assisted research information

Neurocompute uses AI to summarize scientific papers, interpret research signals, and suggest relevant reference links. AI-generated content can be incomplete, misleading, or wrong, and generated links may be irrelevant or unavailable.

Our reviewed outputs have performed strongly to date, but past accuracy is not a guarantee. Verify summaries, scores, claims, and links against the original publication before relying on them.

This platform is for research and education only. It does not provide medical advice, diagnosis, treatment recommendations, or clinical guidance.

Pediatric cancer research intelligence graphic
PEDIATRIC CANCER VISUAL SYSTEM

Open the Research Intelligence Map

Explore the active pediatric oncology analysis view.

Expand Intelligence View →
Full Pediatric cancer research intelligence graphic